林业发展局批准了Stripamil nasal喷雾,这是对PSVT的第一次自我治疗,是一种常见的心脏节奏紊乱症。 The FDA approved etripamil nasal spray, the first self-treatment for PSVT, a common heart rhythm disorder.

林业发展局已核准使用CARDAMYST(etripamil)鼻腔喷雾剂,作为成人首次自发治疗患有口腔呼吸道过敏心痛症(PSVT)的成人的治疗方法,这一疾病影响到200多万美国人。 The FDA has approved CARDAMYST (etripamil) nasal spray as the first self-administered treatment for adults with paroxysmal supraventricular tachycardia (PSVT), a condition affecting over two million Americans. 该药物由里程碑制药公司研制,允许病人在紧急情况之外治疗急性PSVT病症。 The drug, developed by Milestone Pharmaceuticals, allows patients to treat acute PSVT episodes outside emergency settings. 涉及1 800多名参与者的临床试验显示,tripamil在30分钟内实现了近60%病例的正常心脏节奏,中间转换时间为18.5分钟。 Clinical trials involving over 1,800 participants showed etripamil achieved normal heart rhythm in nearly 60% of cases within 30 minutes, with a median conversion time of 18.5 minutes. 耐受性良好，副作用轻微，如鼻塞和喉咙刺激。 It was well-tolerated, with mild side effects like nasal congestion and throat irritation. 预计2026年初零售药店将提供这种药物。 The medication is expected to be available in retail pharmacies in early 2026.